Showing results (1-10 of 269) with videos related to

Sort By:
Pageof 27
Clinical Nuclear Medicine|March 7, 2023
Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory GlioblastomaStuart More, Thurandie Naiker, Nihaad Jacobs, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular diseaseDineo Mpanya, Mike Sathekge, Eric Klug, et al.
Clinical and Translational Imaging|August 15, 2022
SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imagingOlumayowa U Kolade, Akinwale O Ayeni, Anita Brink, et al.
Frontiers in Nuclear Medicine|October 2, 2024
Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumorsKhanyisile Hlongwa, Olumayowa Kolade, Abdulilah Alnabulsi, et al.
British Medical Bulletin|September 11, 2016
F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infectionIsmaheel Lawal, Mike Sathekge
Seminars in Nuclear Medicine|April 24, 2024
Advances in PSMA Alpha TheragnosticsMariza Vorster, Mike Sathekge
Seminars in Nuclear Medicine|January 9, 2026
<sup>18</sup>F-FDG PET/CT for prediction of response in breast cancerMariza Vorster, Mike Sathekge
Cancers|July 24, 2021
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate CancerAmeya D Puranik, Clarisse Dromain, Neil Fleshner, et al.
Clinical Nuclear Medicine|December 30, 2014
Rheumatic fever: a forgotten but still existing cause of fever of unknown origin detected on FDG PET/CTMike Sathekge, Anton Stoltz, Olivier Gheysens
Materials (Basel, Switzerland)|September 10, 2021
Obstacles and Recommendations for Clinical Translation of Nanoparticle System-Based Targeted Alpha-Particle TherapyJanke Kleynhans, Mike Sathekge, Thomas Ebenhan
Pageof 27